Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Purchased by LPL Financial LLC

LPL Financial LLC raised its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 39.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,402 shares of the company's stock after purchasing an additional 15,267 shares during the quarter. LPL Financial LLC's holdings in Cellebrite DI were worth $1,198,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. R Squared Ltd acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at $100,000. Polen Capital Management LLC purchased a new stake in Cellebrite DI during the fourth quarter worth about $222,000. Victory Capital Management Inc. acquired a new stake in shares of Cellebrite DI during the fourth quarter worth about $234,000. HighTower Advisors LLC purchased a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $274,000. Finally, Steward Partners Investment Advisory LLC grew its holdings in shares of Cellebrite DI by 12.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company's stock valued at $299,000 after purchasing an additional 1,463 shares in the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CLBT has been the subject of several recent research reports. JPMorgan Chase & Co. raised their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Finally, Lake Street Capital boosted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI has a consensus rating of "Buy" and an average target price of $23.43.

Cellebrite DI Stock Performance

CLBT stock traded up $0.81 during midday trading on Wednesday, reaching $19.20. 479,896 shares of the company were exchanged, compared to its average volume of 1,405,984. The company has a market cap of $4.60 billion, a price-to-earnings ratio of -13.81, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30. The stock's 50-day simple moving average is $18.79 and its 200 day simple moving average is $20.10.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.